MapLight Therapeutics (MPLT) Other Accumulated Expenses (2024 - 2025)
MapLight Therapeutics recorded quarterly Other Accumulated Expenses of $521000.0 in Q4 2025, down 75.54% quarter-over-quarter from $2.1 million in Q3 2025, and down 66.56% year-over-year from $1.6 million in Q4 2024.
MapLight Therapeutics' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $521000.0 for Q4 2025.
- In Q4 2025, Other Accumulated Expenses fell 66.56% year-over-year to $521000.0; the TTM figure through Dec 2025 stood at $521000.0 (down 66.56% YoY), while the FY2025 annual figure was $521000.0, down 66.56% from the prior year.
- Other Accumulated Expenses came in at $521000.0 for Q4 2025 at MapLight Therapeutics, down from $2.1 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.1 million in Q3 2025 to a low of $521000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 521,000.00 |
| Sep 30, 2025 | 2.13 Mn |
| Dec 31, 2024 | 1.56 Mn |